Literature DB >> 25291291

Cancer cachexia: understanding the molecular basis.

Josep M Argilés1, Sílvia Busquets1, Britta Stemmler2, Francisco J López-Soriano1.   

Abstract

Cancer cachexia is a devastating, multifactorial and often irreversible syndrome that affects around 50-80% of cancer patients, depending on the tumour type, and that leads to substantial weight loss, primarily from loss of skeletal muscle and body fat. Since cachexia may account for up to 20% of cancer deaths, understanding the underlying molecular mechanisms is essential. The occurrence of cachexia in cancer patients is dependent on the patient response to tumour progression, including the activation of the inflammatory response and energetic inefficiency involving the mitochondria. Interestingly, crosstalk between different cell types ultimately seems to result in muscle wasting. Some of the recent progress in understanding the molecular mechanisms of cachexia may lead to new therapeutic approaches.

Entities:  

Mesh:

Year:  2014        PMID: 25291291     DOI: 10.1038/nrc3829

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  107 in total

1.  Validation of the Consensus-Definition for Cancer Cachexia and evaluation of a classification model--a study based on data from an international multicentre project (EPCRC-CSA).

Authors:  D Blum; G B Stene; T S Solheim; P Fayers; M J Hjermstad; V E Baracos; K Fearon; F Strasser; S Kaasa
Journal:  Ann Oncol       Date:  2014-02-20       Impact factor: 32.976

2.  C-reactive protein levels and vitamin d receptor polymorphisms as markers in predicting cachectic syndrome in cancer patients.

Authors:  Tiziana Punzi; Ariele Fabris; Gabriele Morucci; Paolo Biagioni; Massimo Gulisano; Marco Ruggiero; Stefania Pacini
Journal:  Mol Diagn Ther       Date:  2012-04-01       Impact factor: 4.074

3.  Acylated and unacylated ghrelin inhibit doxorubicin-induced apoptosis in skeletal muscle.

Authors:  A P Yu; X M Pei; T K Sin; S P Yip; B Y Yung; L W Chan; C S Wong; P M Siu
Journal:  Acta Physiol (Oxf)       Date:  2014-04-02       Impact factor: 6.311

Review 4.  Regulation of mitofusin-2 expression in skeletal muscle.

Authors:  Antonio Zorzano
Journal:  Appl Physiol Nutr Metab       Date:  2009-06       Impact factor: 2.665

Review 5.  Counteracting inflammation: a promising therapy in cachexia.

Authors:  Josep M Argiles; Francisco J Lopez-Soriano; Silvia Busquets
Journal:  Crit Rev Oncog       Date:  2012

6.  Defining and classifying cancer cachexia: a proposal by the SCRINIO Working Group.

Authors:  Federico Bozzetti; Luigi Mariani
Journal:  JPEN J Parenter Enteral Nutr       Date:  2008-12-24       Impact factor: 4.016

7.  Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group.

Authors:  W D Dewys; C Begg; P T Lavin; P R Band; J M Bennett; J R Bertino; M H Cohen; H O Douglass; P F Engstrom; E Z Ezdinli; J Horton; G J Johnson; C G Moertel; M M Oken; C Perlia; C Rosenbaum; M N Silverstein; R T Skeel; R W Sponzo; D C Tormey
Journal:  Am J Med       Date:  1980-10       Impact factor: 4.965

8.  Elevated energy expenditure in cancer patients with solid tumours.

Authors:  A Hyltander; C Drott; U Körner; R Sandström; K Lundholm
Journal:  Eur J Cancer       Date:  1991       Impact factor: 9.162

9.  Theophylline is able to partially revert cachexia in tumour-bearing rats.

Authors:  Mireia Olivan; Jochen Springer; Sílvia Busquets; Anika Tschirner; Maite Figueras; Miriam Toledo; Cibely Fontes-Oliveira; Maria Inés Genovese; Paula Ventura da Silva; Angelica Sette; Francisco J López-Soriano; Stefan Anker; Josep M Argilés
Journal:  Nutr Metab (Lond)       Date:  2012-08-21       Impact factor: 4.169

Review 10.  Role of microRNAs in skeletal muscle hypertrophy.

Authors:  Keisuke Hitachi; Kunihiro Tsuchida
Journal:  Front Physiol       Date:  2014-01-16       Impact factor: 4.566

View more
  383 in total

Review 1.  The emerging role of skeletal muscle oxidative metabolism as a biological target and cellular regulator of cancer-induced muscle wasting.

Authors:  James A Carson; Justin P Hardee; Brandon N VanderVeen
Journal:  Semin Cell Dev Biol       Date:  2015-12-01       Impact factor: 7.727

2.  The Toll-Like Receptor/MyD88/XBP1 Signaling Axis Mediates Skeletal Muscle Wasting during Cancer Cachexia.

Authors:  Kyle R Bohnert; Praneeth Goli; Anirban Roy; Aditya K Sharma; Guangyan Xiong; Yann S Gallot; Ashok Kumar
Journal:  Mol Cell Biol       Date:  2019-07-16       Impact factor: 4.272

3.  Fenofibrate prevents skeletal muscle loss in mice with lung cancer.

Authors:  Marcus D Goncalves; Seo-Kyoung Hwang; Chantal Pauli; Charles J Murphy; Zhe Cheng; Benjamin D Hopkins; David Wu; Ryan M Loughran; Brooke M Emerling; Guoan Zhang; Douglas T Fearon; Lewis C Cantley
Journal:  Proc Natl Acad Sci U S A       Date:  2018-01-08       Impact factor: 11.205

4.  Imaging skeletal muscle volume, density, and FDG uptake before and after induction therapy for non-small cell lung cancer.

Authors:  M D Goncalves; S Taylor; D F Halpenny; E Schwitzer; S Gandelman; J Jackson; A Lukose; A J Plodkowski; K S Tan; M Dunphy; L W Jones; R J Downey
Journal:  Clin Radiol       Date:  2018-01-06       Impact factor: 2.350

5.  What Can be Learned from the Time Course of Changes in Low-Frequency Stimulated Muscle?

Authors:  Dirk Pette
Journal:  Eur J Transl Myol       Date:  2017-06-24

Review 6.  Adipocyte and lipid metabolism in cancer drug resistance.

Authors:  Yihai Cao
Journal:  J Clin Invest       Date:  2019-07-02       Impact factor: 14.808

7.  Creatine supplementation in Walker-256 tumor-bearing rats prevents skeletal muscle atrophy by attenuating systemic inflammation and protein degradation signaling.

Authors:  Paola S Cella; Poliana C Marinello; Fernando H Borges; Diogo F Ribeiro; Patrícia Chimin; Mayra T J Testa; Philippe B Guirro; José A Duarte; Rubens Cecchini; Flávia A Guarnier; Rafael Deminice
Journal:  Eur J Nutr       Date:  2019-02-26       Impact factor: 5.614

Review 8.  [Prevention and treatment of cachexia : Exercise and nutritional therapy].

Authors:  B Wilms; S M Schmid; K Luley; J Wiskemann; H Lehnert
Journal:  Internist (Berl)       Date:  2016-10       Impact factor: 0.743

9.  Targeting cancer metabolism by simultaneously disrupting parallel nutrient access pathways.

Authors:  Seong M Kim; Saurabh G Roy; Bin Chen; Tiffany M Nguyen; Ryan J McMonigle; Alison N McCracken; Yanling Zhang; Satoshi Kofuji; Jue Hou; Elizabeth Selwan; Brendan T Finicle; Tricia T Nguyen; Archna Ravi; Manuel U Ramirez; Tim Wiher; Garret G Guenther; Mari Kono; Atsuo T Sasaki; Lois S Weisman; Eric O Potma; Bruce J Tromberg; Robert A Edwards; Stephen Hanessian; Aimee L Edinger
Journal:  J Clin Invest       Date:  2016-09-26       Impact factor: 14.808

10.  Understanding tumor anabolism and patient catabolism in cancer-associated cachexia.

Authors:  Alejandro Schcolnik-Cabrera; Alma Chávez-Blanco; Guadalupe Domínguez-Gómez; Alfonso Dueñas-González
Journal:  Am J Cancer Res       Date:  2017-05-01       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.